Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. - Wikidata - awgldk - TriplyDB

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

http://www.wikidata.org/entity/Q36100305

about

Cognitive remission: a novel objective for the treatment of major depression?Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.PPAR-γ agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression.Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin.Fat cell-secreted adiponectin mediates physical exercise-induced hippocampal neurogenesis: an alternative anti-depressive treatment?Pioglitazone could induce remission in major depression: a meta-analysis The neurobiological correlates of childhood adversity and implications for treatment.Pioglitazone is an effective treatment for patients with post-stroke depression combined with type 2 diabetes mellitus Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity Pathways to new drug discovery in neuropsychiatry.A Possible Role for Pioglitazone in the Management of Depressive Symptoms in Metabolic Syndrome Patients (EPICAMP Study): A Double Blind, Randomized Clinical Trial.Epigenetic differences in monozygotic twins discordant for major depressive disorder Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response.Inflammation in Depression and the Potential for Anti-Inflammatory Treatment Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.The integrative management of treatment-resistant depression: a comprehensive review and perspectives.Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.Depression is Associated with Increased Risk for Metabolic Syndrome in Latinos with Type 2 Diabetes.Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression The Importance of Clinical Trials in Drug Development Personalized medicine: a tailor made medicine.Therapeutic strategies for treatment of inflammation-related depression.Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.

P2860

Q26775386-777EC782-90AA-47F9-875C-A8898ABC6E75 Q26782993-3BD4F476-BA59-403D-8258-FF4BF140AAEC Q27303048-C0A987FE-F55B-4884-AA0A-21BB9A6A4CA1 Q33960389-B6F68BDB-768A-4BA4-AC7C-95E49AAD3C98 Q34444287-55C2BEED-4AE2-4026-AD70-A343062A8D8F Q34467840-53317901-9F1C-49B5-AEFB-87F7C0144E1F Q34548227-3F31A09F-9376-4733-B2BB-C34A6CB060B1 Q35743326-6BFD88EF-D31D-4EAC-986E-2A9163D7C886 Q35942767-AA08E6FA-3186-448B-9AB1-884C4C1EE6D8 Q36132836-DA920BCB-9E55-4CC6-BD41-CADF67C1B4AA Q36594394-9854DA80-770F-4F8C-AC2A-AEA70038359C Q36980014-FC6E9E38-76DE-4B7C-B17F-BE5E996EC574 Q37061840-10E4D4CB-0E59-4522-B40D-1CE8264D7812 Q37161489-02A5E4D3-1E43-4C2B-9A65-78203B273E60 Q37310528-78E0587E-7CEC-44A6-A648-7002CE161293 Q38157027-3BA10A23-B3FD-42A7-ACA7-AE49B3A899BD Q38181363-EF7B9A44-F73B-468B-B50C-502F8148C631 Q38454097-390FC2CE-9461-49FE-BAC1-91A688D902BF Q38740026-38415C29-B442-4635-AFA1-3A581B81DC71 Q38990885-E7CA7776-C98E-4305-8380-913AF8C5F63C Q42363180-B8247BDC-FAB8-4302-AD42-D3CE58D5901E Q42988081-D48AC2F3-310F-4920-B137-1BD4E70CDEFC Q47785792-A328C56C-A5BD-4ABC-ABA6-BAC64861A772 Q47889297-3197B856-8AED-4DFA-898B-BDED47898E3E Q48086898-E85BD485-8CFA-42E3-8211-C17FDC28DE9E Q48128615-F47E1E43-FB1A-4E68-9E94-97BD4D6990D1 Q50235068-92136391-F506-4D8D-B048-666A9F208C1A Q50306200-9132C645-8D53-46C7-802E-F20CDC8AFFC5

P2860

Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.

http://www.wikidata.org/entity/Q36100305

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pioglitazone adjunctive therap ...... lind placebo-controlled trial.

@ast

Pioglitazone adjunctive therap ...... lind placebo-controlled trial.

@en

type

label

Pioglitazone adjunctive therap ...... lind placebo-controlled trial.

@ast

Pioglitazone adjunctive therap ...... lind placebo-controlled trial.

@en

prefLabel

Pioglitazone adjunctive therap ...... lind placebo-controlled trial.

@ast

Pioglitazone adjunctive therap ...... lind placebo-controlled trial.

@en

P1433

Q36100305-02DF3396-A711-4656-9488-C2C33F3567F8

P1476

Q36100305-EBC324BE-F998-4F4F-8C73-E89D4B84348F

P2093

Q36100305-7B69EEE3-B213-4E82-B2AB-2FD2ECEA0909

Q36100305-9CBE50C6-A338-4385-9A50-900F423E6E3B

Q36100305-C6ED2681-34F8-436C-840A-968E6E0AC5BB

Q36100305-D9D6FE14-170A-4A4A-A4C4-7586A6BD646B

P2860

Q36100305-08693154-6BF8-4451-8962-ED08BE6F73C2

Q36100305-18F425A1-A579-4B9F-B148-89D6C1719277

Q36100305-19FCA2B6-2F51-4AFF-B0A5-B196A76E19FA

Q36100305-1B118B6A-EF03-4E39-8F90-023045FEE7F3

Q36100305-1C9AFF18-D65D-414D-9493-A364EB857EC2

Q36100305-2381E89B-148F-402A-A2A0-4E81B174FFC7

Q36100305-2DD4FB45-60BA-4611-B1FB-CF6AF24942E4

Q36100305-33B6FA6C-8F90-450D-A571-F76C159E07B2

Q36100305-38E5F23F-BEF3-43B6-BF90-6CEE4976ACF9

Q36100305-3E53C8F5-F830-4105-8202-4BF822B434EE

P2888

Q36100305-2333C030-0996-4E0B-9E5C-60D3B7136D68

P304

Q36100305-17F8C223-1F31-4C17-A969-8065179BE845

P31

Q36100305-A66EC2E4-C477-4346-8AAE-09929C2C326F

P356

Q36100305-A4290F27-68DC-448A-B643-F118317792CF

P407

Q36100305-4851A1A7-376B-4745-9AAD-30BA526E42A3

P433

Q36100305-7BFF61EC-68A4-4D88-98A0-2F7810E68097

P478

Q36100305-F3F5C2B2-C065-43F5-BA9E-81F768CBAF9E

P50

Q36100305-2CD96F42-D252-4DDB-A77B-90B54706D501

P577

Q36100305-CA18B9D7-D1E5-42E9-B969-314567BD884A

P5875

Q36100305-92CE7268-FE2A-4424-B699-A87237DEB231

P698

Q36100305-5E7D62C9-83D9-4D62-A63F-D2EF52C088B4

P921

Q36100305-7864D1EA-67BE-4BFD-8ADF-E09BD8059CCA

P932

Q36100305-359B2BB9-F595-4D1C-B310-53E1A4F4952F

P356

P1433

Neuropsychopharmacology

P1476

Pioglitazone adjunctive therap ...... blind placebo-controlled trial

@en

P2093

Amirhossein Modabbernia

http://www.w3.org/2001/XMLSchema#string

Khatereh Sepanjnia

http://www.w3.org/2001/XMLSchema#string

Mandana Ashrafi

http://www.w3.org/2001/XMLSchema#string

Mohammad-Jafar Modabbernia

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease.

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.

Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study.

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

The STAR*D Project results: a comprehensive review of findings.

Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity.

Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.

P2888

P304

2093-2100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2012.58

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Shahin Akhondzadeh

P577

2012-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224878328

http://www.w3.org/2001/XMLSchema#string

P698

22549115

http://www.w3.org/2001/XMLSchema#string

P921

P932

3398722

http://www.w3.org/2001/XMLSchema#string